Stimulus-responsive biomaterials for Helicobacter pylori eradication.
Tiantian Shan1, Xi Chen1, Xinxuan Zhou2
1State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China; Department of Operative Dentistry and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Journal of Advanced Research
|December 31, 2023
Summary
Stimulus-responsive biomaterials offer a novel approach to combat Helicobacter pylori (H. pylori) infections, overcoming limitations of traditional antibiotics. These smart materials utilize environmental cues for targeted and efficient eradication of H. pylori.
Area of Science:
- Biomaterials Science
- Infectious Diseases
- Drug Delivery Systems
Background:
- Helicobacter pylori (H. pylori) is a type I carcinogen linked to gastric cancer, infecting nearly half the world's population.
- Standard antibiotic therapies face challenges due to stomach barriers, microbial resistance, and limited efficacy.
- Stimulus-responsive biomaterials present an emerging strategy for intelligent and targeted H. pylori therapy.
Purpose of the Study:
- To review obstacles in current H. pylori treatment.
- To summarize advances in stimulus-responsive biomaterials for H. pylori eradication.
- To analyze future prospects of smart biomaterials in H. pylori therapy.
Main Methods:
- Review of recent literature on stimulus-responsive biomaterials.
- Elucidation of working mechanisms and antibacterial performance under various stimuli (pH, enzymes, light, magnetic, ultrasound).
- Analysis of endogenous and exogenous stimuli for enhanced therapeutic effects.
Main Results:
- Responsive biomaterials leverage endogenous or exogenous stimuli for antibacterial activity.
- Endogenous stimuli enhance targeting and utilize physiological barriers for H. pylori eradication.
- Exogenous stimuli prolong action time, pinpoint infection sites, and reduce side effects.
Conclusions:
- Stimulus-responsive biomaterials offer precise and effective H. pylori eradication strategies.
- These smart materials overcome limitations of conventional therapies.
- Future development holds promise for improved H. pylori treatment outcomes.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
410
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
410
01:26Peptic Ulcer Disease IV: Management
95
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
95
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
492
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
492
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
430
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
430
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
129
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
129
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
444
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
444